Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 491-499

  Wheeler, Heather E ^a   Gamazon, Eric R ^a   Wing, Claudia ^a   Njiaju, Uchenna O ^a   Njoku, Chidiamara ^a   Baldwin, Robert Michael ^b   Owzar, Kouros ^c   Jiang, Chen ^c   Watson, Dorothy ^c   Shterev, Ivo ^c   Kubo, Michiaki ^d   Zembutsu, Hitoshi ^d   Winer, Eric P ^e   Hudis, Clifford A ^f   Shulman, Lawrence N ^e   Nakamura, Yusuke ^a,d   Ratain, Mark J ^a   Kroetz, Deanna L ^b   Cox, Nancy J ^a   Dolan, Mary Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RIKEN   (Japan)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADJUVANT THERAPY; ANIMAL CELL; ARTICLE; BREAST CANCER; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; NERVE FIBER GROWTH; NEUROPATHY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RAT; RFX2 GENE; SENSORY PERIPHERAL NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; TRANSCRIPTION FACTORS;

EID: 84872549256     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2618     Document Type: Article

References (45)

1. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101. J Clin Oncol 2012;30: 4071-6.
2. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapyinduced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011;90: 377-87.
3. Baldwin RM,Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18: 5099-109.
4. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12: 854-9.
5. Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, et al. CYP2C8-3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012;134: 401-10.
6. Leandro-Garcia LJ, Leskela S, Jara C, Green H, Avall-Lundqvist E, Wheeler HE, et al. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 2012;18: 4441-8.
7. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011;18: 85-95.
8. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, et al. Association of ABCB1 genotypes with paclitaxelmediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42: 2893-6.
9. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A 2007;104: 9758-63.
10. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genomewide association and drug response biomarkers. PLoS ONE 2009;4: e7765.
11. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genomewide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 2004;101: 11809-14.
12. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 2012;13: 55-70.
13. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2011 Aug 16. [Epub ahead of print].
14. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010;28: 4674-82.
15. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME. Wholegenome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics 2009;3: 128-42.
16. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011;17: 5490-500.
17. Mitra AK, Crews K, Pounds S, Cao X, Downing JR, Raimondi S, et al. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia 2011;25: 1354-6.
18. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ, et al. Genetic variation predicting Cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011;17: 5801-11.
19. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 2011;157: 265-72.
20. Cox NJ, Gamazon ER, Wheeler HE, Dolan ME. Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther 2012;92: 425-7.
21. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, et al. SCAN: SNP and copy number annotation. Bioinformatics 2010;26: 259-62.
22. Njiaju UO, Gamazon ER, Gorsic LK, Delaney SM, Wheeler HE, Im HK, et al. Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics 2012;22: 498-507.
23. Abecasis GR, Cookson WO, Cardon LR. Pedigree tests of transmission disequilibrium. Eur J Hum Genet 2000;8: 545-51.
24. Price AL, Tandon A, Patterson N, Barnes KC, Rafaels N, Ruczinski I, et al. Sensitive detection of chromosomal segments of distinct ancestry in admixed populations. PLoS Genet 2009;5:e1000519.
25. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 2009;84: 210-23.
26. Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, et al. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS ONE 2011;6:e21920.
27. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55: 997-1004.
28. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficientmeta-analysis of genomewide association scans. Bioinformatics 2010;26: 2190-1.
29. Shterev ID, Jung SH, George SL, Owzar K. permGPU: using graphics processing units in RNA microarray association studies. BMC Bioinformatics 2010;11:329.
30. O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, et al. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 2012;118: 4063-73.
31. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 2010;107: 9287-92.
32. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, et al. Genetic architecture of transcript-level variation in humans. AmJ Hum Genet 2008;82: 1101-13.
33. Stark AL, Zhang W, Mi S, Duan S, O'Donnell PH, Huang RS, et al. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J 2010;10: 505-12.
34. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9: 671-5.
35. Geldof AA. Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J Cancer Res Clin Oncol 1995;121: 657-60.
36. Verstappen CC, Postma TJ, Geldof AA, Heimans JJ. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res 2004;24: 2337-41.
37. Teo YY, Small KS, Kwiatkowski DP. Methodological challenges of genome-wide association analysis in Africa. Nat Rev Genet 2010;11: 149-60.
38. Horvath GC, Kistler WS, Kistler MK. RFX2 is a potential transcriptional regulatory factor for histone H1t and other genes expressed during the meiotic phase of spermatogenesis. Biol Reprod 2004;71: 1551-9.
39. Wolfe SA, Wilkerson DC, Prado S, Grimes SR. Regulatory factor X2 (RFX2) binds to the H1t/TE1 promoter element and activates transcription of the testis-specific histone H1t gene. J Cell Biochem 2004;91: 375-83.
40. Purvis TL, Hearn T, Spalluto C, Knorz VJ, Hanley KP, Sanchez-Elsner T, et al. Transcriptional regulation of the Alstrom syndrome gene ALMS1 by members of the RFX family and Sp1. Gene 2010;460: 20-9.
41. Swoboda P, Adler HT, Thomas JH. The RFX-type transcription factor DAF-19 regulates sensory neuron cilium formation in C. elegans. Mol Cell 2000;5: 411-21.
42. Dubruille R, Laurencon A, Vandaele C, Shishido E, Coulon-Bublex M, Swoboda P, et al. Drosophila regulatory factor X is necessary for ciliated sensory neuron differentiation. Development 2002;129: 5487-98.
43. Gajiwala KS, Chen H, Cornille F, Roques BP, Reith W, Mach B, et al. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature 2000;403: 916-21.
44. Halder SK, Fink M, Waterman MR, Rozman D. A cAMP-responsive element binding site is essential for sterol regulation of the human lanosterol 14alpha-demethylase gene (CYP51). Mol Endocrinol 2002;16: 1853-63.
45. Oshiro C, Marsh S, McLeod H, Carrillo M, Klein T, Altman R. Taxane Pathway. Pharmacogenet Genomics 2009;19: 979-83.